Study Group: Formulary Design Experts(?)
Council Members in this Study Group: 205
Request a survey with this Study Group
Leading Experts in this Study Group
Independent Contractor
Independent Contractor - Arnold Greensher
Arnold Greensher, MD, is a Medical Director for the commercial managed care section of Schaller Anderson Healthcare, Arizona. He is Board certified in Family Practice and Pediatrics and fellowship trained in Genetics. Dr. Greensher lectures widely on issues related to Medical Malpractice, Risk Management...
Owner/Consultant
The Right Way
Josh Valdez, DBA, is Owner of The Right Way, a full service healthcare consulting organization. For the previous four years, Dr. Valdez served as the Senior Vice President of Health Care Management for WellPoint Pacific Zone, one of three Regions comprising WellPoint, Inc, the leading health plan in...
VP Operations
Cumberland Pharmaceuticals, Inc.
Leo Pavliv, RPh, MBA, is Vice President Operations at Cumberland Pharmaceuticals in Tennessee. His job responsibilities include directing overall drug development activities for numerous products, regulatory affairs, product development, clinical and non-clinical development, manufacturing, and quality...
Joe Renner, MBACEO and part owner
Zydus Pharmaceuticals USA Inc
Joseph D. Renner, MBA, is CEO of Zydus Pharmaceuticals (USA) Inc., the US affiliate of Zydus Cadila, an Indian generic pharmaceutical manufacturer. Prior to this, Mr. Renner was the EVP/COO of Geneva Pharmaceuticals, a generics manufacturer and division of Novartis. In addition, Mr. Renner spent 17...
Avram Goldberg, MD,FACRAssistant Professor
Albert Einstein College of Medicine
Avram Goldberg, MD, FACR, is an Attending Physician at North Shore University Hospital and an Assistant Professor at the Albert Einstein College of Medicine, New York. He is part of the Division of Rheumatology where he is responsible for treatment of autoimmune and musculoskeletal diseases including...
Senior Medical Director
CIGNA Government Services
Robert Hoover, Jr., MD, MPH, is Jurisdiction C Durable Medical Equipment Medical Director at CIGNA Government Services. In his role at CIGNA Government Services, he is responsible for coverage, coding, and documentation for durable medical equipment, orthotics and prosthetics in fee-for-service Medicare....
Tim Gallagher, RPhExecutive Vice President of Pharmacy Operations
Astrup Drug, Inc.
Tim Gallagher, RPh, is the Executive Vice President of Pharmacy Operations at Astrup Drug, Inc. Minnesota. He manages all aspects of pharmacy operations for the company. Mr. Gallagher has been a practicing pharmacist for 23 years in both the chain and independent community pharmacy setting. He has also...
Director in Health and Productivity Practice
BUCK CONSULTANTS, INC - CC
Vikram Singh, MBA, is a Director in the Health and Productivity Practice at Buck Consultants. His expertise is in the financial and business aspects of pharmacy benefit management. Mr. Singh provides strategic advice in the areas of pharmacy benefit and health care finance, and on mergers and acquisitions...
Related Study Groups
| Study Group Name | Members |
|---|---|
| Pharmacists (US) | 2081 |
| Generic Drug Economic Experts | 679 |
| Economic Experts on Managed Care | 657 |
| Managed Care Experts | 631 |
| Economic Experts on Formulary Designs (US) | 54 |
| Medicare Experts | 455 |
| Managed Care Pricing Trends Experts | 252 |
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
The Smart study has done the LABAs in. At no time was a LABA suggested to be used alone except in this study. The participants were all comers from all MDs able to write an rx. There was no proper patient selection and no proper follow up for the majority of the patients. Many likely used this...
Lipitor may indeed be better than Simvasatain, but an observational study will NOT prove this.
Please see my comments on the ALLHAT Hypertension study. Newer is not better. The biggest difference from my standpoint is formulation to keep the patent runing. In hard economic times we really need to consider this for the patient and NOT BIG pharma.
Unfortunately there are no reasonable studies comparing older drugs with GOOD efficacy that are now generic with newer agents. ALLHAT was perhaps the last. Also with many patients requiring more than a single agent, it is hard to use the results of that study to make clinical decisions.
If you look at the underlying pathophysiology it makes perfect sense. Asthma is mostly an eosinoplphillic based disease, where steriod use will decrease their number. COPD is for the most part a neutrophillic process where steriods should have a moinor role.
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Managed Care Health Insurer, For-Profit
- Managed Care Health Insurer, Non-Profit
- Consultancy, Healthcare-Focused
- Facility, Academic Medical Center
- Pharmaceutical Benefits Manager, Large >10 M Lives
- Blue Cross/Blue Shield Non-Profit Health Insurer
- Facility, Non-Academic/Community Hospital
- Pharmaceutical Benefits Manager, Small <10 M Lives
- Non-Academic Community Hospital or Clinic
- Office Based Private Practice or Clinic
- Consultancy, Pharma-Focused
- Pharmaceuticals Manufacturer
Most Common Job Types:
- Pharmacist - RPh/PharmD
- Director
- Physician - Attending Physician
- President
- Medical Director
- Owner
- Manager